Please try another search
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
James Nathanielsz | 47 | 2007 | Executive Chairman, CEO, CFO, Treasurer & Secretary |
Joseph M. Chalil | 48 | 2015 | Member of Scientific Advisory Board |
Klaus Kutz | - | 2010 | Chief Medical Officer & Member of Scientific Advisory Board |
John F. Smyth | - | - | Member of Scientific Advisory Board |
Maria A. Garcia | - | 2016 | Member of Scientific Advisory Board |
Ralf Brandt | 54 | 2019 | Member of Scientific Advisory Board |
Macarena Peran | - | 2016 | Member of Scientific Advisory Board |
Josef Zelinger | 70 | 2020 | Independent Non-Executive Director |
Juan Antonio Marchal Corrales | - | 2016 | Member of Scientific Advisory Board |
Julian Norman Kenyon | 74 | 2008 | Chief Scientific Officer, CTO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review